Which SSRIs or SNRIs are contraindicated with fezolinetant?

Published

Fluvoxamine (a selective serotonin reuptake inhibitor [SSRI]) and viloxazine (a serotonin and norepinephrine reuptake inhibitor [SNRI]) are examples of CYP1A2 inhibitors. Fezolinetant is contraindicated in individuals using CYP1A2 inhibitors

  • Several electronic resources include tables of CYP substrates, inhibitors, and inducers (e.g., FDA, UpToDate® Lexidrug™, Indiana University).1–3
  • It is important to be aware that drug-drug interactions may differ from one drug database to another, and from the fezolinetant approved product label information.

  • Fezolinetant is a substrate of CYP1A2 and concomitant use with drugs that are weak, moderate, or strong CYP1A2 inhibitors increases the maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC) of fezolinetant.4
  • The SSRI fluvoxamine is a strong CYP1A2 inhibitor.5 Following concomitant use with fluvoxamine, fezolinetant Cmax increased by 80% and AUC increased by 840%4
  • Any treatment for VMS (prescription, over the counter or herbal), as well as strong and moderate CYP1A2 inhibitors (including fluvoxamine), were prohibited during the fezolinetant Phase 3 trials.6
  • The following SSRIs and SNRIs were used concomitantlya by participants in the Phase 3 trails of fezolinetant (52-week study period; safety analysis setb):6

Placeboc

(n = 952)

Fezolinetant

30 mg

Totald

(n = 1103)

Fezolinetant

45 mg

Totale

(n = 1100)

SSRIs (total)

74 (7.8%)

86 (7.8%)

64 (5.8%)

Citalopram / citalopram hydrobromide

27 (2.8%)

20 (1.8%)

25 (2.3%)

Escitalopram / escitalopram oxalate

13 (1.4%)

16 (1.5%)

14 (1.3%)

Fluoxetine / fluoxetine hydrochloride

10 (1.1%)

20 (1.8%)

11 (1.0%)

Paroxetine / paroxetine hydrochloride

5 (0.5%)

7 (0.6%)

4 (0.4%)

Sertraline / sertraline hydrochloride

21 (2.2%)

26 (2.4%)

12 (1.1%)

SNRIs (total)

31 (3.3%)

36 (3.3%)

33 (3.0%)

Desvenlafaxine / desvenlafaxine succinate monohydrate

3 (0.3%)

4 (0.4%)

3 (0.3%)

Duloxetine / duloxetine hydrochloride

12 (1.3%)

11 (1.0%)

14 (1.3%)

Levomilnacipran hydrochloride

1 (0.1%)

0

0

Venlafaxine / venlafaxine hydrochloride

15 (1.6%)

21 (1.9%)

16 (1.5%)

a Concomitant medications are defined as any medications that participants took after the first dose of study medication and either up to 30 days from last dose of study drug or first dose of study drug during the extension period, whichever came sooner.

b SAF: All randomized participants assessed according to the treatment they received at first dose.

c Placebo includes 175 participants from SKYLIGHT 1 and 167 participants from SKYLIGHT 2 who received placebo for 12 weeks, and 610 participants who received placebo for 52 weeks in SKYLIGHT 4.

d Fezolinetant 30 mg Total includes 152 participants who received fezolinetant 30 mg for 40 weeks (re-randomized after Week 12 from placebo to fezolinetant 30 mg for the active treatment extension period in SKYLIGHT 1 and 2), and 951 participants who received fezolinetant 30 mg for 52 weeks in SKYLIGHT 1, 2 and 4.

e Fezolinetant 45 mg Total includes 151 participants who received fezolinetant 45 mg for 40 weeks (re-randomized after Week 12 from placebo to fezolinetant 45 mg for the active treatment extension period in SKYLIGHT 1 and 2), and 949 participants who received fezolinetant 45 mg for 52 weeks in SKYLIGHT 1, 2, and 4.

  1. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. FDA. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Accessed 3JUN2024.

  2. Lexidrug Online. Inhibitors and Inducers of Cytochrome P450 Enzymes (Lexi-Drugs). Available at: https://online.lexi.com/lco/action/home. Accessed 19APR2024.

  3. Drug Interactions Flockhart TableTM. Indiana University. Available at: https://drug-interactions.medicine.iu.edu/MainTable.aspx. Accessed 19APR2024.

  4. VEOZAH [package insert]. Northbrook, IL, USA: Astellas Pharma, Inc. Available at: https://www.astellas.com/us/system/files/veozah_uspi.pdf.

  5. Lexicomp Online. Inhibitors and Inducers of Cytochrome P450 Enzymes (Lexi-Drugs). Available at: https://online.lexi.com/lco/action/home.

  6. Data on file.

find-my-msl

Find My MSL

Medical Science Liaisons are available to help answer your scientific questions.

submit

Submit an Inquiry

For any medical inquiries, please submit your question online to Astellas Medical Information or call or fax your inquiry.

Astellas Phone: 1-800-727-7003

Fax: 1-877-829-7942

adverse

Report an Adverse Event or Product Complaint

Report adverse events and product complaints to Astellas or FDA MedWatch.

Astellas Phone: 1-800-727-7003

FDA MedWatch: 1-800-FDA-1088

Hours: M–F, 8 AM–4:30 PM (CT)